治疗眼后段新生血管疾病给药途径的研究进展  

Advances in Drug Delivery for the Treatment of Posterior Eye Segment Neovascular Diseases

作　　者：孙莹 王凤山[1] SUN Ying;WANG Feng-shan(Institute of Biochemical and Biotechnological Drugs,Key Laboratory of Chemical Biology of Natural Products(Ministry of Education),School of Pharmaceutical Sciences,Shandong University,Jinan 250012,China)

机构地区：[1]山东大学药学院生化与生物技术药物研究所,天然产物化学生物教育部重点实验室,济南250012

出　　处：《中国药学杂志》2020年第12期973-978,共6页Chinese Pharmaceutical Journal

基　　金：国家自然科学基金项目资助(81872788)。

摘　　要：由于眼球结构的特殊性,眼后段新生血管疾病的治疗一直是眼科疾病及其治疗药物研究的热点与难点。对这类疾病临床上常采用的治疗方法,如玻璃体注射抗血管内皮生长因子药物,价格昂贵且副作用较大。研究者们探索了一系列患者顺应性更好、眼后段药物浓度更高、疗效更好的治疗方法。为了更好地研究和开发治疗眼后段新生血管疾病的药物,笔者对治疗眼后段新生血管疾病面临的主要挑战以及给药途径的研究进展进行综述。Due to the complex of the ocular structure,the treatment of the posterior eye segment neovascular diseases has been a hot and difficult point in the field of ophthalmic disease and correspongding drug research.The clinical treatment methods for this kind of diseases,such as intravitreal injection of anti-vascular endothelial growth factor(anti-VEGF)drugs,are usually costly and have potential side-effects.Researchers have explored a series of treatment methods with better patient compliance,higher drug concentration in the posterior eye segment and better therapeutic effect.In order to research and develop the ideal drugs for the treatment of the posterior eye segment neovascular diseases,we review the main challenges and the advances in drug delivery for the treatment of this kind of diseases in this paper.

关 键 词：眼后段新生血管疾病 眼球屏障 药物递送 

分 类 号：R969[医药卫生—药理学]